Educational reference, not medical advice. This page summarizes information from published research and regulatory filings for educational purposes. It is not a recommendation to use any compound and should not replace guidance from a licensed healthcare provider. Most peptides discussed here are not approved for the uses described.
What it is
This is a commercial pre-mixed combination of two small peptides — GHK-Cu and KPV — co-lyophilized in a single vial. Both peptides are short (GHK-Cu is three residues plus a bound copper ion; KPV is the three-residue C-terminal fragment of α-melanocyte-stimulating hormone) and both have separate research bases in skin and inflammation.
The blend is supplied by compounding pharmacies and research-peptide vendors, frequently in topical or injectable formats. Some preparations are designed for topical use in research contexts (creams, serums) and others as injectable lyophilized powders. Ratios vary; a typical injectable preparation contains roughly equal milligram amounts of each peptide.
The combination is marketed within skin-protocol research channels. It has not been clinically evaluated as a single product in any published study.
History
The two components have distinct histories:
- GHK-Cu was identified by Loren Pickart at UCSF in 1973 during studies of why young plasma supported liver tissue better than old plasma. The peptide-copper complex became a mainstream cosmetic ingredient in the 1980s and 1990s based on topical evidence of improved fibroblast proliferation and collagen synthesis.
- KPV was characterized as the minimal anti-inflammatory fragment of α-MSH in the late 1990s by the Catania and Lipton groups. Most published evidence comes from rodent colitis models and in vitro inflammation work.
The blend itself appeared in research-peptide retail in the early 2020s. No peer-reviewed publication describes the combined product.
Regulatory status
Topical GHK-Cu is approved as a cosmetic ingredient in the United States, the European Union, Japan, and most jurisdictions, and has decades of safety data in skincare. Injectable GHK-Cu and KPV have no regulatory approval anywhere in the world. The combined blend is supplied through research-chemical vendors labeled not for human use, or through compounding pharmacies for topical applications.
How researchers describe its action
The mechanism descriptions for each component come from separate literature:
- GHK-Cu is documented in cell and topical animal studies as a stimulator of collagen and elastin synthesis, an inducer of antioxidant enzymes (superoxide dismutase, glutathione peroxidase), and a copper carrier for lysyl oxidase. A 2010 Connectivity Map analysis reported that GHK modulates the expression of more than 4,000 human genes in skin fibroblasts.
- KPV is described as a suppressor of NF-κB signaling in macrophages and intestinal epithelium, with antimicrobial activity demonstrated in vitro by the Cutuli group in 2000. It does not bind melanocortin receptors with appreciable affinity, which is why it does not produce the pigmentation effects of the parent α-MSH hormone.
How the two peptides interact when combined — whether they act on overlapping or independent pathways in skin tissue — has not been studied.
Half-life and dosing intervals
Both components are rapidly cleared from circulation:
- GHK-Cu: approximately 30–60 minutes.
- KPV: approximately 20–30 minutes.
Observational protocols described in research-peptide channels typically involve subcutaneous injection once or twice daily, with per-injection mass in the 1–3 mg range across both peptides. Topical formulations deliver the peptides through the stratum corneum at substantially lower concentrations (commonly 0.05–0.2% for GHK-Cu).
Reconstitution example
A 10 mg blend vial (5 mg of each peptide) reconstituted with 2 mL of bacteriostatic water yields a total peptide concentration of 5 mg/mL. On a 1 mL U-100 insulin syringe, 10 units (0.10 mL) delivers 0.5 mg of total peptide, split as 0.25 mg of each component.
The blue color contributed by the copper in GHK-Cu is a useful sanity check that the GHK-Cu complex is intact after reconstitution. Discoloration or precipitate indicates degradation.
What to know
- Topical use is documented; injectable use is not. Most published evidence for both components applies to topical or oral formulations, not injection.
- No combined clinical data. The two-peptide blend has not been evaluated in any peer-reviewed trial.
- Copper exposure. GHK-Cu carries copper as part of the complex; Wilson's disease and certain chronic kidney conditions are absolute reasons to avoid copper supplementation.
- Storage. Refrigerate lyophilized vials and protect from light. After reconstitution, refrigerate and use within four weeks per stability data for each component.
- Reported side effects. Component user reports describe injection-site irritation; GHK-Cu's copper content can cause local discoloration if administered superficially. No controlled human safety profile exists for the combined blend.
Sources
- 1.Pickart L, Margolina A (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences.
- 2.Maquart FX et al. (1988). Stimulation of collagen synthesis by GHK-Cu. FEBS Letters.
- 3.Catania A et al. (2004). Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacological Reviews.
- 4.Cutuli M et al. (2000). Antimicrobial effects of α-MSH peptides. Journal of Leukocyte Biology.